NEW YORK – Array Genomics is in the midst of rolling out its microarray-based test for staging and grading bladder cancer based on urine samples. The molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.
While Array Genomics has seen some initial demand for the test, which is currently paid for out of pocket, the company is keen to support more studies that will raise the profile of the firm and its product and perhaps see it adopted into European urology guidelines.